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Abstract The widespread use of trastuzumab in the past
decade has led to a significant and measureable improve-
ment in the survival of patients with human epidermal
growth factor receptor-2 (HER2) overexpressing breast
cancer, and in many ways has redefined the natural history
of this aggressive breast cancer subtype. Historically, sur-
vival in patients with HER2-positive disease was dictated
by the systemic disease course, and what appears to be
the central nervous system (CNS) tropism associated with
HER2-amplified tumors was not clinically evident. With
improved systemic control and prolonged survival, the
incidence of brain metastases has increased, and CNS
disease, often in the setting of well-controlled extracranial
disease, is proving to be an increasingly important and
clinically challenging cause of morbidity and mortality in
patients with HER2-positive advanced breast cancer.
This review summarizes the known clinical data for the
systemic treatment of HER2-positive CNS metastases and
includes information about ongoing clinical trials of novel
therapies as well as emerging strategies for early detection
and prevention.
Keywords Metastatic breast cancer  Brain metastases 
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Introduction
Breast cancer is the second most common solid malignancy
that metastasizes to the central nervous system (CNS) [1].
Epidemiologic studies estimate that the incidence of brain
metastases (BM) in women with metastatic breast cancer
(MBC) is 10–16 % [2, 3], but autopsy reports suggest rates
as high as 30 % [2, 4–6]. Morbidity and mortality of
patients with breast cancer is generally driven by extent
and progression of non-CNS disease. BM often present late
in the disease course, long after development of visceral
metastases, and thus, historically have not had a significant
impact on overall survival (OS). As a result, finding new
treatments that target BM has not been prioritized, and
nearly all clinical trials have excluded these patients.
However, as patients live longer due to advances in
human epidermal growth factor receptor-2 (HER2)-tar-
geted and systemic therapy, it appears that the incidence of
BM is increasing, often in the setting of well-controlled
systemic disease. As a result, controlling or preventing
BM in patients with HER2-amplified MBC has become
an increasingly important treatment consideration for
oncologists.
HER2 overexpression is a well-established risk factor
for CNS metastases. Approximately 20–25 % of all breast
cancers overexpress HER2, and prior to trastuzumab,
HER2-amplified tumors were associated with a more
aggressive phenotype and shorter OS than non-amplified
tumors [7]. Trastuzumab has redefined the prognosis of
HER2-positive disease, and the future for patients with
HER2-positive tumors will only improve as promising anti-
HER2-targeted agents currently in preclinical and clinical
development move into the clinic. Because trastuzumab
does not cross the blood–brain barrier (BBB), the CNS
serves as a sanctuary for metastatic disease in the setting of
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sustained extracranial control and improved survival. In
addition, BM may be associated with debilitating neuro-
logical symptoms such as headaches, motor deficits, and
seizures [8]. For these reasons, HER2-positive BM may
have an increasing impact on the morbidity and mortality
of breast cancer patients. Thus, treatments for HER2-
positive BM are a growing unmet clinical need deserving
of dedicated clinical trials evaluating novel therapeutics
and strategies. This review will discuss BM in HER2-
amplified MBC, with detailed discussion of current treat-
ment modalities and investigative approaches.
Incidence of HER2-positive brain metastases
While there are few data directly comparing the incidence
of BM in patients with metastatic HER2-positive versus
HER2-negative disease, numerous studies have reported
high rates of BM in those with HER2-positive disease
[9–15] relative to that described in historical epidemiologic
studies where HER2 status was unknown or unavailable
[2, 3]. In the registHER study, a prospective observational
study of 1,012 patients with newly diagnosed HER2-posi-
tive MBC, 37.3 % of patients developed BM at a median
follow-up of 29 months [10]. Retrospective studies in
patients treated with trastuzumab have reported similar
rates, generally ranging from 25 to 48 % [9, 11–15].
The increased incidence of BM in HER2-positive dis-
ease can possibly be attributed to an inherent biologic
predisposition. Pestalozzi et al. reviewed data from 9,524
women with early breast cancer from 10 adjuvant clinical
trials (1978–1999), none of whom received anthracycline,
taxane, or trastuzumab therapy. The 10-year cumulative
incidence of CNS as a site of first relapse was higher in
patients with HER2-positive versus HER2-negative disease
(2.7 vs 1.0 %, P \ 0.01) [16], as was true for the 10-year
incidence of CNS recurrence at any time (6.8 vs 3.5 %,
P \ 0.01). Although only 41 % of patients had HER2
status available (34.3 % were HER2-negative and 6.4 %
were HER2-positive), these data suggest that HER2-
amplified tumors may have an inherent biologic tropism for
the CNS independent of treatment and other prognostic
factors. These findings are consistent with 2 smaller studies
[17, 18]; Kallioniemi et al. investigated the site of first
relapse in 319 patients with trastuzumab-naive breast
cancer. HER2-positive tumors metastasized 3 times more
often to the lungs, liver, and brain compared with HER2-
negative tumors (P = 0.0002) [17]. In a Canadian popu-
lation-based study of 664 patients with early-stage breast
cancer, HER2 overexpression was the most significant
independent risk factor for future BM [18]. A higher
incidence of CNS metastases was observed in HER2-
positive than HER2-negative patients (9 vs 1.9 %, hazard
ratio [HR], 4.23; 95 % confidence interval [CI], 1.84–9.74;
P = 0.0007) in this study (where few patients [8 %]
received trastuzumab) [18]. Taken together, these obser-
vational data suggest that HER2-positive cells may exhibit
tissue tropism that cannot be explained by circulatory
patterns alone. Based on these observations and others,
there is interest in identifying molecular signatures pre-
dictive of organ-specific metastases [19, 20]. Such gene
signatures could facilitate the design of prevention trials by
identifying patients at high risk of developing BM, which
would allow for the evaluation of prophylactic measures to
potentially inhibit or delay metastasis. In addition, there are
efforts to develop a gene signature to predict early versus
late development of BM in patients with HER2-positive
MBC [21].
It has been hypothesized that the incidence of BM in
patients with HER2-positive MBC has increased due to the
success of trastuzumab therapy. Because trastuzumab does
not cross the BBB due to its large size (185 kDa), the CNS
may be largely immune to its antitumor effects. Improved
systemic control and OS in the setting of poor CNS coverage
allows patients to develop BM that would have previously
gone undiagnosed due to rapid extracranial disease pro-
gression and death in the pre-trastuzumab era. Although
retrospective studies have reported conflicting results
[15, 22, 23], several studies have supported this hypothesis,
reporting an increased frequency of BM in the setting of
controlled extracranial disease in patients who receive
trastuzumab as first-line therapy for metastatic disease
[12, 13, 24]. For example, Burstein et al. demonstrated that
approximately 10 % of patients receiving first-line trast-
uzumab-based regimens had isolated CNS recurrence as a
first progression event. Although initial progression at
peripheral sites was still more common, patients receiving
trastuzumab had a higher incidence of isolated CNS recur-
rence than those receiving chemotherapy alone [24].
Three large adjuvant trastuzumab trials have reported
CNS events. NSABP B-31 and NCCTG N9831 reported a
higher incidence of isolated BM as the first site of recur-
rence in patients randomized to trastuzumab versus control
(21 [2.4 %] vs 11 [1.3 %] in trial B-31 and 12 [1.5 %] vs 4
[0.5 %] in trial N9831) [25], while in the HERA trial, there
was no difference in CNS metastases between the 2 treat-
ment arms (1.5 vs 1.3 %) [26]. NSABP B-31 was the only
trial to report cumulative incidence of BM (first or sub-
sequent) and showed no significant difference between
groups (28 [3.2 %] vs 35 [4.0 %], respectively; P = 0.35)
[25]. These data suggest that imbalances in first events are
due to improved extracranial systemic control with trast-
uzumab. Two meta-analyses of the 3 adjuvant trials
(including [6,000 patients) reported an increased risk of
BM among patients treated with trastuzumab [27, 28].
Similarly, another meta-analysis of [9,000 patients
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reported an increased risk of BM as the first site of disease
recurrence among HER2-positive breast cancer patients
treated with adjuvant trastuzumab [29].
Prognosis of HER2-positive brain metastases
Survival of patients with CNS metastases is poor, with
1- and 2-year survival rates of 20 and \2 %, respectively
[30]. In the pre-trastuzumab era, evidence suggested
shorter OS in patients with HER2-positive than HER2-
negative BM [31]; however, several retrospective studies
and 1 prospective observational study reported longer OS
and survival after diagnosis of BM in patients with trast-
uzumab-treated HER2-positive disease versus HER2-neg-
ative or HER2-positive patients not receiving trastuzumab.
In trastuzumab-treated patients, median survival from
diagnosis of CNS metastases has varied across studies,
ranging from 12 to 25 months [12, 15, 22, 32–35].
In a Korean single-center review of patients receiving
palliative chemotherapy for HER2-positive MBC, systemic
extracranial disease control and lack of progression of
extracranial disease for C12 months after diagnosis of BM
were among the independent prognostic factors for death
from CNS disease [15]. Proportions of deaths from BM and
extracranial systemic disease in the pre-trastuzumab era
were 45.7 versus 37.1 %, respectively (n = 35), and 59.5
versus 11.9 % in trastuzumab-treated patients (n = 42).
Current and emerging systemic treatments for HER2-
positive brain metastases
Historically, BM trials have included patients with various
solid tumors. There are few trials testing novel therapies
specifically in breast cancer BM, and even fewer solely
in patients with HER2-positive disease (Table 1). Other
challenges include non-uniform standards of response
assessment and difficulty in accessing tissue for definitive
diagnosis. Local therapy consisting of surgery followed
by whole-brain radiotherapy (WBRT), stereotactic radio-
surgery (SRS), or WBRT alone remains the standard of care
for initial management of BM due to MBC as well as BM
arising from many other primary tumor sites; a full discus-
sion of local therapy control is beyond the scope of this
review. The remainder of the review will focus on existing
and emerging systemic therapies for HER2-positive BM.
Chemotherapy
Use of standard cytotoxic chemotherapy for the treatment
of BM is limited by poor drug penetration across an
intact BBB, drug efflux mediated by high expression of
P-glycoprotein (PgP) in brain capillary endothelial cells,
and development of BM late in the disease course when the
tumor is resistant to multiple lines of chemotherapy [8, 36–
39]. Despite this, several agents have demonstrated CNS
activity, likely as a result of increased vessel permeability
associated with tumor metastases and radiation effects [40,
41]. Evidence suggests both size of metastases [42] and
breast cancer subtype [43] impact the degree of BBB dis-
ruption. An ongoing trial is evaluating the penetrability of
various chemotherapeutic and targeted agents, comparing
intratumoral and blood drug concentrations in patients
with C1 resectable breast cancer BM who receive 1 dose of
chemotherapy or targeted therapy (trastuzumab or lapati-
nib) prior to surgery (NCT00795678).
In recent years, a limited number of newer chemother-
apeutic agents have demonstrated activity in prospective
studies of MBC-related BM (Table 2). In general, the most
promising agents for CNS disease are agents that are active
against breast cancer, regardless of BBB permeability. For
example, temozolomide, although relatively permeable, is
not very active against breast cancer and has shown limited
activity in the CNS [44–47]. In contrast, cisplatin has
shown clinical activity with MBC-associated BM both as a
single agent and in combination with other chemotherapies
and WBRT [48–51]. Similarly, there are provocative ret-
rospective data with capecitabine, an agent with well-
established efficacy in breast cancer, which has been pro-
posed to cross the BBB via the human concentrative
nucleoside transporter (hCNT) [52, 53]. A phase II trial is
evaluating capecitabine monotherapy in patients with
MBC and CNS progression after WBRT alone or with SRS
and no prior systemic therapy for BM (NCT01077726).
Phase II trials are also evaluating WBRT ± capecitabine in
breast cancer-associated BM (NCT00977379/XERAD,
NCT00570908).
Anti-HER2 therapies
Trastuzumab
Although penetration of trastuzumab across an intact BBB
is limited, it may be enhanced when the BBB is compro-
mised by radiation, BM, or meningeal carcinomatosis [54,
55]. There are no clinical studies directly examining the
impact of trastuzumab on BM; however, retrospective
studies suggest improved outcomes in patients developing
BM on trastuzumab, who then continue trastuzumab after
radiation [34, 35]. Although this benefit is likely due to
better systemic control, 1 study reported a trend toward
longer time to CNS progression, suggesting a possible
direct CNS effect, although this remains controversial [34].
It is unknown whether trastuzumab functions as a
radiosensitizer. Trastuzumab has been shown to enhance
Breast Cancer Res Treat (2013) 137:1–12 3
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radiation-induced apoptosis of breast cancer cells in a
HER2 level-dependent manner in preclinical studies [56],
but clinical studies are lacking. One small single-arm study
of concurrent trastuzumab and WBRT demonstrated safety
and activity with a radiographic response rate (RR) of
74 % [57]. Randomized studies of WBRT versus concur-
rent trastuzumab plus WBRT have not been performed.
However, radiation may improve the ability of trastuzumab
to cross the BBB. In a study of 6 patients with HER2-
positive BM undergoing treatment with trastuzumab and
WBRT, the ratio of trastuzumab concentrations in serum
and cerebral spinal fluid (CSF) was 420:1 prior to radiation
and 76:1 after radiation [55].
It is possible that the efficacy of trastuzumab against
intracerebral metastases could be increased with improved
delivery across the BBB. This is supported by data
demonstrating improved survival with trastuzumab intra-
cerebral microinfusion (ICM) in HER2-positive breast
cancer xenografts, without evidence of clinical or histo-
logical toxicity, compared to intraperitoneal trastuzumab or
ICM with saline [58]. Several case reports, primarily in
HER2-positive leptomeningeal disease, have suggested
intrathecal trastuzumab demonstrated clinical benefit
and was generally well tolerated [59–65]; however, this
remains experimental. A phase I/II trial of intrathecal
trastuzumab in patients with HER2-positive leptomenin-
geal disease is ongoing (NCT01325207).
Lapatinib
Lapatinib is an oral, reversible, small molecule tyrosine kinase
inhibitor (TKI) targeting HER2 and EGFR/HER1 [66].
Table 1 Planned or active clinical trials for patients with HER2-positive MBC with brain metastases
Trial Planned
accrual
Population Treatment Primary
endpoint(s)
Status
Trastuzumab
Phase I/II
(NCT00397501)
78 HER2-positive or HER2-negative MBC
with CNS or brain metastases
Trastuzumab, methotrexate,
and carboplatin with osmotic
BBB disruption
OS Not yet
recruiting
Phase II
(NCT01363986)
66 HER2-positive breast cancer and C1
measurable brain metastasis
Trastuzumab plus WBRT Brain RR Recruiting
Afatinib
Phase II [100]
(NCT01441596;
LUX-breast 3)
120 HER2-positive MBC with CNS metastasis
(C1 measurable brain lesion)
Afatinib, afatinib/vinorelbine,
or investigator’s choice of
therapy
Benefit at
12 weeksa
Recruiting
Lapatinib
Phase I
(NCT00614978;
LAPTEM)
18 HER2-positive MBC with recurrent or
progressive brain metastases after surgery,
WBRT, or SRS (or unsuitable for these
standard treatments)
Lapatinib plus temozolomide MTD and
DLT
Ongoing,
not
recruiting
Phase I
(NCT00470847)
39 HER2-positive MBC, C1 parenchymal brain
lesion, and CNS progression
Lapatinib plus WBRT MTD and
feasibility
Ongoing,
not
recruiting
Neratinib
Phase II
(NCT01494662)
45 HER2-positive MBC, C1 parenchymal brain
lesion, and any number and type of prior
therapy (other than neratinib) allowed
Neratinib (progressive brain
metastases) or neratinib/
surgical resection (if eligible
for craniotomy)
Recruiting
Everolimus
Phase II
(NCT01305941)
35 HER2-positive breast cancer with brain
metastases (C1 measurable brain lesion), and
any number and type of prior therapy (other
than mTOR inhibitors or Navelbine) allowed
Everolimus plus trastuzumab
and vinorelbine
Intracranial
RRb
Recruiting
BBB blood–brain barrier, CNS central nervous system, DLT dose-limiting toxicity, HER2 human epidermal growth factor receptor-2, MBC
metastatic breast cancer, MTD maximum tolerated dose, OS overall survival, RR response rate, SRS stereotactic radiosurgery, WBRT whole-brain
radiotherapy
Includes trials indexed on clinicaltrials.gov for which results are forthcoming, as of October 2012
a Benefit described as absence of CNS or extra-CNS progression
b Modified RECIST criteria
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Lapatinib is approved in combination with capecitabine in
patients with HER2-positive trastuzumab-treated MBC [67],
as well as with letrozole in patients with hormone receptor-
and HER2-positive advanced disease [68]. Although lapatinib
is a small, lipophilic molecule (581 Da) that can cross the
BBB, it is a substrate of PgP, breast cancer resistance protein 1
(BCRP1), and other drug efflux proteins. Preclinical studies of
PgP and BCRP1 knockout mice treated with lapatinib dem-
onstrate increased brain:plasma lapatinib concentrations
(1.2–1.7) compared with wild-type mice (0.03–0.04) [69].
Table 2 Selected phase II trials of chemotherapy for mixed HER2 status MBC-associated brain metastases
Agent(s) Patient population/setting N
Total
N
BC
N
HER2?
Efficacy
Cisplatin
Cisplatin [48] Previously untreated brain
metastases from solid
tumors
34 8 NR RR (brain) = 42 % (14/33) among all tumor types;
RR (brain) = 87.5 % (7/8, 4 CRs and 3 PRs) in BC
Cisplatin ? etoposide [49] Surgically ineligible brain
metastases from solid
tumors
14 4 NR RR (brain) = 14 % (2/14; 1 PR in BC)
Cisplatin ? etoposide [50] First-line for brain
metastases
from BC, NSCLC, or
melanoma
116 56 NR RR (brain) = 38 % (21/56, 7 CRs and 14 PRs) in BC;
TTP (brain) = 17 weeks in BC;
Median OS = 31 weeks in BC
Cisplatin ? vinorelbine ?
WBRT [51]
Previously untreated brain
metastases from BC
25 25 7 RR (brain) = 76 % (19/25, 3 CRs and 16 PRs);
RR (systemic) = 44 % (1 CR, 10 PRs);
Median PFS (brain) = 5.2 months;
Median PFS (systemic) = 3.7 months;
Median OS = 6.5 months
Temozolomide
Temozolomide ? cisplatin
[44]
Brain metastases from
solid tumors
32 15 NR RR (brain) = 6/15 in BC;
Median TTP (systemic) = 2.9 months among all tumor
types;
Median OS = 5.5 months among all tumor types
Temozolomide ? WBRT
[45]
Brain metastases from
solid tumors
33 7 NR RR (brain) = 57.6 % after 6 cycles among all tumor types;
RR (brain) = 2/7 in BC;
Median RFS = 11 months among all tumor types;
Median OS = 12 months among all tumor types
Temozolomide (protracted
low-dose) ? WBRT [46]
Brain metastases from
BC or NSCLC
27 12 NR RR (brain) = 48.1 % among all tumor types;
RR (brain) = 7/12 (1 CR, 6 PRs) in BC;
Median TTP (brain) = 6 months (95 % CI, 5.1–6.8) among
all tumor types;
Median OS = 8.8 months (95 % CI, 6.8–8.9) among all
tumor types
Temozolomide (dose
dense) [47]
Brain metastases from
BC, NSCLC, or
melanoma
157 51 NR RR (brain) = 6 % (10/157, 1 CR and 9 PRs) among all
tumor types;
RR (brain) = 4 % (2/51, 2 PRs) in BC;
Median OS = not reached in BC
Capecitabine
Capecitabine ? lapatinib
[75]
HER2-positive brain
metastasis from BC
43 43 43 RR (brain) = 67 % in BC;
Median TTP (brain) = 5.5 months in BC
Capecitabine ? lapatinib
[76]
HER2-positive brain
metastasis from BC
13 13 13 RR (brain) = 38 % (5/13; all 5 PRs) in BC
BC breast cancer, CI confidence interval, CR complete response, HER2 human epidermal growth factor receptor-2, NSCLC non-small cell lung
cancer, NR not reported, OS overall survival, PFS progression-free survival, PR partial response, RFS relapse-free survival, RR response rate
(CR ? PR), TTP time to progression, WBRT whole-brain radiotherapy
Breast Cancer Res Treat (2013) 137:1–12 5
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These data may, at least in part, explain the modest CNS
clinical activity seen with lapatinib.
A pilot phase II trial evaluated lapatinib monotherapy in
39 patients with HER2-positive BM that developed during
trastuzumab therapy [70]. This study reported a 2.6 % RR
in the CNS per RECIST criteria, which did not meet the
prespecified cut off for further investigation. An explor-
atory analysis suggested that volume change may be a
more appropriate primary efficacy endpoint in trials of
CNS disease. A multicenter phase II trial evaluated lapat-
inib monotherapy in 242 patients with HER2-positive BM
progressing after trastuzumab and radiation [71]. Enroll-
ment completed in 12 months, reflecting the demand for
clinical trials in this population. The primary endpoint was
C50 % volumetric reduction in the sum of all lesions.
Volumetric analysis in 200 patients demonstrated C50 %
reduction in 6 % of patients and C20 % reduction in 21 %.
Volumetric reduction was associated with improved pro-
gression-free survival; diarrhea (13 %) was the only grade
3 to 4 toxicity affecting C5 % of patients. A phase I study
is exploring lapatinib plus WBRT in patients with BM
from HER2-overexpressing breast cancer (NCT00470847).
Fifty patients entered an extension phase testing the
combination of lapatinib plus capecitabine at the time of
progression [71]. A C50 and C20 % volume reduction in
CNS lesions was observed in 20 and 40 % of patients,
respectively. The clinical significance of such a response is
not clear; however, an exploratory analysis showed that
improvement in time to progression (TTP) was observed in
patients with C10 % volumetric reduction compared with
those with lesser or no reduction (P = 0.04) [70]. In the
United Kingdom expanded access program of lapatinib and
capecitabine for HER2-positive MBC, 34 patients had CNS
disease, the majority of whom had received prior radiation
(94 %). CNS response by RECIST criteria was seen in
21 % of patients (including 1 complete response [CR])
[72]. The Korean expanded access program of lapatinib
and capecitabine for HER2-positive MBC [73] and an
Italian analysis (2 centers) comparing lapatinib and cape-
citabine against trastuzumab-based regimens in patients
with BM and prior trastuzumab therapy [74] reported
clinical benefit as well. Results from LANDSCAPE, a
phase II study to determine if patients with HER2-positive
MBC-associated BM who receive lapatinib plus capecita-
bine can avoid or delay WBRT, support a high CNS RR of
67 % among 43 evaluable patients, with median TTP of
5.5 months and median time to WBRT of 8.3 months [75].
It is important to note that the individual contributions of
lapatinib versus capecitabine versus the combination are
unknown, as many of these patients had not received prior
capecitabine, which appears to have independent CNS
activity. A randomized phase II study compared lapatinib
plus capecitabine to lapatinib plus topotecan for patients
with HER2-positive breast cancer BM progressing after
trastuzumab and radiotherapy. Although the study was
stopped before full enrollment, CNS activity was noted for
lapatinib/capecitabine and not for lapatinib/topotecan [76].
Whether lapatinib monotherapy can decrease the risk of
developing CNS metastases is unknown. Clinical data are
limited to an exploratory analysis of the phase III registry
trial of lapatinib and capecitabine versus capecitabine
alone in 399 patients with HER2-positive MBC previously
treated with trastuzumab. Significantly fewer patients had
symptomatic CNS progression as the first progression
event with the combination versus monotherapy (2 vs 6 %;
P = 0.045) [77], but the overall incidence of CNS metas-
tases was not reported [78].
Lapatinib pharmacokinetics data in the CNS are lacking,
largely because lapatinib is highly insoluble and cannot be
measured in the CSF. Preclinical studies have demon-
strated that higher doses of lapatinib can lead to higher
concentrations in brain tissue [69]. This is supported by
clinical reports showing tolerability, activity, and increased
CSF penetration with high-dose HER-family small mole-
cule TKIs in lung cancer patients [79, 80], suggesting that
CNS activity of small molecule HER2-targeted therapies
may be optimized through alternate dosing strategies.
Neratinib
Neratinib, an irreversible oral TKI against HER1/EGFR,
HER2, and HER4, has demonstrated activity in trast-
uzumab-naive and trastuzumab-refractory disease [81–83],
but clinical trials to date have excluded patients with active
CNS metastases. A phase II open-label, single-arm study of
neratinib in patients with HER2-overexpressing breast
cancer with BM is currently recruiting (NCT01494662).
The primary endpoint is response based on volumetric
assessment. Neratinib concentrations will be measured in
the plasma, as well as tumor tissue and CSF in patients
undergoing craniotomy. Cognitive function will also be
assessed.
Afatinib
Afatinib (BIBW 2992), an irreversible ErbB family
inhibitor of HER1/EGFR, HER2 [84], and HER4 [85], has
shown preliminary activity in a phase II study in HER2-
positive MBC after failure of trastuzumab, with 4 partial
responses (PRs) and 15 patients with stable disease (SD)
among 35 evaluable patients [86]. Early clinical data also
suggest afatinib may be active against BM, based on a
phase I study during which a patient with NSCLC expe-
rienced PR of BM with continued afatinib therapy [87].
A phase II study (NCT01441596) comparing the efficacy
6 Breast Cancer Res Treat (2013) 137:1–12
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and safety of afatinib alone, afatinib in combination with
vinorelbine, and the investigator’s choice of chemo-
therapeutic regimen in patients with HER2-overexpressing
MBC with BM who have had prior trastuzumab and/or
lapatinib therapy is currently recruiting.
Pertuzumab
Pertuzumab (PerjetaTM), a HER2-targeted monoclonal
antibody, was recently approved in combination with
trastuzumab and docetaxel for the treatment of chemo-
therapy-naive HER2-positive MBC [88]. Currently, there
are no data regarding the efficacy of pertuzumab in treating
BM; it is expected that the activity will be similar to
trastuzumab in terms of its limited ability to cross the BBB.
Other targeted therapies
Everolimus (Afinitor), an inhibitor of mammalian target of
rapamycin (mTOR), was recently approved in combination
with exemestane for the treatment of postmenopausal
women with advanced hormone receptor-positive, HER2-
negative breast cancer after treatment failure with letrozole
and anastrozole [89]. A phase II, open-label, single-arm
study (NCT01305941) of daily everolimus plus weekly
vinorelbine and trastuzumab in breast cancer patients with
HER2-positive BM is currently recruiting patients.
Novel cytotoxic agents
Several novel cytotoxic agents with the ability to cross the
BBB have recently been evaluated in patients with BM
arising from several solid tumors, including breast cancer.
A single-arm, phase II study evaluating the efficacy and
safety of sagopilone, an epothilone B analogue and tubulin-
stabilizing agent, in 15 breast cancer patients with BM
reported that 2 patients (1 with HER2-positive disease)
achieved a CNS PR (overall CNS RR, 13.3 %), with a
median progression-free survival and OS of 1.4 and
5.3 months, respectively [90]. In a phase I, dose-escalation
study, GYN1005, a novel peptide-drug conjugate of pac-
litaxel covalently linked to angiopep-2, was reported to
shrink brain lesions arising from several primary tumor
sites, including the breast [91].
Antiangiogenic therapy
Preclinical and clinical data suggest that the aggressive
phenotype of HER2-overexpressing breast cancers may be
mediated, in part, by upregulation of vascular endothelial
growth factor (VEGF), and provide rationale for combining
anti-HER2 and anti-VEGF therapies for the treatment of
HER2-overexpressing breast cancers [92–94]. Limited data
are available utilizing antiangiogenic therapy for BM, but a
case series of 4 patients with CNS metastases (n = 3 brain;
n = 1 meningeal) from MBC described 1 CR and 3 PRs with
bevacizumab plus paclitaxel [95]. One of the patients who
achieved PR of a cerebellar lesion had HER2-positive dis-
ease previously treated with chemotherapy/trastuzumab and
lapatinib/capecitabine. A phase II trial is evaluating bev-
acizumab plus carboplatin in patients with progressive BM
from MBC (not HER2-positive specific), allowing prior
trastuzumab therapy (NCT01004172). Preliminary results
from another phase II trial evaluating bevacizumab plus
etoposide and cisplatin in breast cancer patients with
progressive BM (not HER2-positive specific) after WBRT
showed that 9 out of 12 evaluable patients (75 %) achieved a
CNS objective response (defined as a C50 % reduction in the
volumetric sum of all measureable CNS lesions) with 6
patients (50 %) achieving C80 % volumetric reduction [96].
Early detection and prevention
Given the increased incidence of BM in HER2-positive
MBC, early detection strategies may offer improved out-
comes. At this time, there are no data to support early
screening for occult BM. In a study of 155 asymptomatic
patients with MBC undergoing brain MRI screening for
clinical trial participation, 15 % of patients had occult CNS
metastases [97]. The authors found no difference in OS
between patients with occult metastases detected by
screening and patients with symptomatic CNS metastases
from a separate cohort. HER2-overexpression was predic-
tive of CNS involvement in multivariate analysis [97]. In a
more recent study, 80 patients with HER2-overexpressing
MBC without neurologic symptoms were screened for
occult BM every 3 months [98]. Occult metastases were
detected in 36 % of patients, 90 % of whom received
WBRT. Compared with a separate cohort receiving WBRT
for symptomatic BM, use of early WBRT decreased the
rate of death from BM (16 vs 48 %; P = 0.009) but had no
impact on OS (53 vs 51 months, P = 0.944).
An ongoing randomized trial is being conducted in women
with HER2-positive MBC without neurologic symptoms
evaluating gadolinium-enhanced MRI of the brain once every
4 months versus every 12 months for early detection of CNS
metastases (NCT00398437); OS is the primary endpoint.
Prophylactic cranial irradiation (PCI) with WBRT, which has
shown benefit in certain malignancies, does not have an
established role in breast cancer [99]. However, a phase I trial
of PCI in patients with HER2-positive MBC was recently
completed (NCT00916877), and a randomized phase III trial
is evaluating a 6-week course of taxane/trastuzumab alone or
with concurrent PCI (NCT00639366). Lastly, a phase II trial
evaluating temozolomide for the prevention of BM in patients
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(including HER2-positive) who achieve response or SD for
C6 months with first-line chemotherapy for MBC was
recently terminated due to poor accrual (NCT00638963/Study
P05225).
Conclusions
The field of HER2-positive breast cancer is among the
most active areas of breast cancer research today. As a
result, numerous novel HER2-targeted agents are in vari-
ous phases of clinical development, many of which have
shown promising clinical activity with regard to systemic
control. Thus, CNS metastases will likely be an increas-
ingly common occurrence for patients with HER2-positive
MBC, leading to the need to find effective strategies for the
treatment, management, and prevention of CNS disease.
The future for patients with HER2-positive breast cancer is
bright; however, clinical and research efforts must focus on
ways to target and penetrate the BBB. This will require
dedicated clinical trials for patients with active CNS dis-
ease, including trials of novel drugs, alternate modes of
treatment delivery, and multimodality therapies.
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